Mathew Palmer, Chief Growth and Commercial Officer, will be in Barcelona THIS WEEK!
Accelagen is pleased to confirm that Mathew Palmer, Chief Growth and Commercial Officer, will be representing our team at the upcoming Outsourcing in Clinical Trials (OCT) Europe 2025 conference in Barcelona 29-30 April. As a leading Contract Research Organisation (CRO) headquartered in Australia, Accelagen is committed to advancing clinical programs worldwide through fast, flexible, and high-quality solutions – and Mathew’s presence at OCT highlights just that.
Partnering for Progress: What Sets Accelagen Apart
For European biotech and pharmaceutical companies aiming to accelerate their early-stage development, Australia offers an unmatched advantage. Through Australia’s efficient regulatory environment, attractive R&D Tax Incentive (returning up to 43.5 cents on the dollar), and access to world-class scientific expertise, Accelagen delivers a compelling, risk-mitigated pathway for Phase I through to Phase III clinical studies.
During OCT Europe, Mathew will be connecting with companies interested in:
- Rapid study startup timelines
- High-quality data generation suitable for U.S. and European submissions
- Access to a safe, reliable, and economically favorable clinical trial environment amid ongoing global uncertainties
- True strategic partnership — not just vendor relationships — to maximise asset value and patient outcomes
Listening First, Partnering Strategically
Rather than focusing solely on promoting Accelagen’s growth — including the company’s impressive expansion and 15-year anniversary — Mathew’s primary goal is to listen. He looks forward to hearing the challenges, goals, and needs of biopharma innovators and finding meaningful ways Accelagen can integrate expertise, challenge conventional thinking, and ultimately deliver better results.
“Our end goal is to get new drugs to patients,” says Mathew. “We aren’t just a service provider; we’re a true partner invested in enhancing asset value, meeting timelines, and delivering with quality.”
Meet Mathew Palmer at OCT Europe 2025
Mathew will be available for one-on-one meetings throughout the event. Mathew is actively booking meetings and is eager to discuss how Accelagen’s tailored regulatory and clinical solutions can support your development pipeline.
If you’re attending OCT Europe 2025 and want to explore how Australia can be a strategic advantage for your next clinical trial, make sure to connect with Mathew. Meetings are being arranged directly through outreach and informal scheduling prior to the conference — if you’d like to reserve time, please reach out soon.
About Accelagen
Accelagen is a globally adept, Australian-based CRO providing customized, agile, and cost-effective clinical solutions. With over 200 years of combined leadership experience across strategic consultation, clinical trial delivery, regulatory affairs, biometrics, medical, and safety services, Accelagen partners with pharma and biotech companies worldwide to accelerate the future of human health and wellness.